Table 2.
Risk of death for atrial cardiopathy markers.
| Markers | Total patients | AF patients excluded | |||
|---|---|---|---|---|---|
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | ||
| PTFV1 > 5000 μV·ms | Model 1 | 2.17 (1.53–3.08) | <0.0001 | 2.28 (1.58–3.30) | <0.0001 |
| Model 2 | 1.70 (1.18–2.45) | 0.004 | 1.77 (1.21–2.59) | 0.003 | |
| aIAB | Model 1 | 1.57 (1.23–2.02) | 0.0004 | 1.54 (1.18–2.00) | 0.001 |
| Model 2 | 1.47 (1.14–1.91) | 0.003 | 1.43 (1.09–1.88) | 0.009 | |
| Prolonged P-wave duration | Model 1 | 1.22 (0.97–1.53) | 0.09 | 1.21 (0.96–1.54) | 0.11 |
| Model 2 | 1.17 (0.93–1.48) | 0.18 | 1.16 (0.91–1.48) | 0.23 | |
| Prolonged P-wave dispersion | Model 1 | 1.17 (0.93–1.47) | 0.19 | 1.22 (0.96–1.55) | 0.10 |
| Model 2 | 1.16 (0.92–1.47) | 0.21 | 1.21 (0.95–1.54) | 0.12 | |
| Prolonged PR interval | Model 1 | 1.32 (0.94–1.84) | 0.11 | 1.29 (0.91–1.84) | 0.16 |
| Model 2 | 1.26 (0.89–1.78) | 0.19 | 1.18 (0.82–1.71) | 0.37 | |
| Supraventricular tachycardia | Model 1 | 0.81 (0.63–1.04) | 0.10 | 1.02 (0.76–1.37) | 0.88 |
| Model 2 | 0.95 (0.73–1.24) | 0.73 | 0.95 (0.70–1.29) | 0.76 | |
| Excessive atrial ectopy | Model 1 | 1.09 (0.81–1.48) | 0.57 | 1.09 (0.79–1.49) | 0.61 |
| Model 2 | 1.03 (0.75–1.41) | 0.84 | 1.07 (0.77–1.48) | 0.69 | |
| Severe LA enlargement | Model 1 | 2.55 (1.63–3.98) | <0.0001 | 2.30 (0.85–6.18) | 0.10 |
| Model 2 | 1.41 (0.87–2.29) | 0.16 | 1.72 (0.63–4.68) | 0.29 | |
Model 1: Model 1 was adjusted for age, sex.
Model 2: Model 2 was adjusted for age, sex, NIHSS, atrial fibrillation, hypertension, diabetes mellitus, dyslipidemia, current tobacco smoker, heart failure, coronary artery disease, peripheral artery disease, myocardial infarction, prior history of stroke or TIA, medication at discharge (antiplatelet, anticoagulants, antihypertensive agent, hypoglycemic agent, lipid-lowering agent).
AF: atrial fibrillation; aIAB: advanced interatrial block; CI: confidence interval; HR: hazard ratio; LA: left atrial; PTFV1: P-wave terminal force in V1.